Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | F10 | P00742 | 12/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6577783 | 0.89 | SMN1; SMN2 (0.59) | SMN1; SMN2GAALMNAF10ATM | |
| SCHEMBL5733762 | 0.87 | F10 (0.72) | SMN1; SMN2GAALMNAF10ATM | |
| SCHEMBL6580032 | 0.85 | ATM (0.56) | SMN1; SMN2GAALMNAF10ATM | |
| SCHEMBL6304930 | 0.83 | F10 (0.69) | SMN1; SMN2GAALMNAF10ATM | |
| SCHEMBL6427668 | 0.82 | F10 (0.56) | SMN1; SMN2GAALMNAF10ATM | |
| SCHEMBL5735220 | 0.82 | F10 (0.61) | SMN1; SMN2GAALMNAF10ATM | |
| SCHEMBL6300303 | 0.82 | F10 (0.68) | SMN1; SMN2GAALMNAF10ATM | |
| SCHEMBL5734527 | 0.81 | ATM (0.54) | SMN1; SMN2GAALMNAF10ATM | |
| SCHEMBL5734081 | 0.81 | F10 (0.67) | SMN1; SMN2LMNAF10ATML3MBTL1 | |
| SCHEMBL6305602 | 0.79 | F10 (0.53) | SMN1; SMN2GAALMNAF10ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1000033-B1 | HETEROCYCLIC DERIVATIVES WHICH INHIBIT FACTOR XA | ASTRAZENECA AB (SE) | 2004-05-06 | — | — | EP | disclosed |
| EP-1367054-A1 | Heterocyclic factor Xa inhibitors | AstraZeneca AB (SE) | 2003-12-03 | — | — | EP | disclosed |
| US-20020193375-A1 | Heterocyclic derivatives which inhibit factor Xa | ZENECA LIMITED | 2002-12-19 | — | — | US | disclosed |
| US-6458793-B1 | HETEROCYCLIC DERIVATIVES, OR PHARMACEUTICALLY-ACCEPTABLE SALTS THEREOF, WHICH POSSESS ANTITHROMBOTIC AND ANTICOAGULANT PROPERTIES AND MORE ACCORDINGLY USEFUL IN METHODS OF TREATMENT OF HUMANS OR ANIMALS. THE INVENTION ALSO RELATES TO PROCESSES | ZENECA LIMITED (GB) | 2002-10-01 | — | — | US | disclosed |
| EP-1000033-A1 | HETEROCYCLIC DERIVATIVES WHICH INHIBIT FACTOR XA | AstraZeneca UK Limited (GB) | 2000-05-17 | — | — | EP | disclosed |
| WO-1999006371-A1 | HETEROCYCLIC DERIVATIVES WHICH INHIBIT FACTOR XA | ZENECA LIMITED (GB) | 1999-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193375-A1 | Heterocyclic derivatives which inhibit factor Xa | F12, TFPI, F2 | SMN1; SMN2 4213/4885GAA 609/4885LMNA 623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.